Under active development. Data is being added and corrected on an hourly basis.

← Back to Peptides
Tirzepatide structure

Tirzepatide

Metabolic
Approved Research
95%
Low Risk
1/5

Also Known As

Mounjaro · Zepbound

Overview

Tirzepatide is a novel dual incretin agonist targeting both GIP and GLP-1 receptors. Shows significant efficacy in metabolic research.

Mechanism of Action

Activates both GIP and GLP-1 receptors, providing complementary effects on insulin, glucagon, appetite, and metabolism.

Quick Reference

Common Dose 2.5mg-15mg
Frequency Once weekly
Half-Life ~5 days
Storage Refrigerate.

Notes

Titrate slowly. Start at lowest dose.